IMCR · Current Report (Form 8-K) · Filed January 9, 2026

Immunocore Holdings PLC — 8-K exhibit

ef20062561_ex99-3.htm

Immunocore Holdings PLC on Boardroom Alpha

Exhibit 99.3

1 NSCLC = Non-small cell lung cancer 2 Program is not HLA restricted (i.e. universal for all populations). *ID = Infectious diseases Leading bispecific TCR pipeline Candidate Target (HLA type) Indication Pre IND Phase 1 Phase 2 Phase 3 Approved gp100-A02 Uveal (ocular) melanoma Adjuvant uveal (ocular) melanoma 2L+ advanced cutaneous melanoma PRAME Programs Brenetafusp (PRAME-A02) 1L advanced cutaneous melanoma Combos Ovarian, NSCLC1 Additional solid tumors IMC-P115C (PRAME-A02-HLE) Multiple solid tumors IMC-R117C PIWIL1-A02 Colorectal and GI cancers IMC-M113V Gag-A02 Human Immunodeficiency Virus (HIV) IMC-S118AI PPI x PD1-A02 Type 1 Diabetes IMC-U120AI CD1a x PD1 (non-HLA restricted)2 Atopic Dermatitis Oncology ID* Autoimmune TEBE-AM PRISM-MEL-301 ATOM sponsored by

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer